New Triple-Drug cocktail shows promise for tough breast cancer

This study tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy (bevacizumab and paclitaxel) helps people with a certain type of advanced breast cancer (HR-positive, HER2-negative). The trial enrolled 281 participants whose cancer had spread or could not be removed by surgery. The main goal was to see if the combination slowed cancer growth better than chemotherapy alone.